Latest News

In a recent study, researchers report that a series of biomarkers, or biological signals, associated with white blood cell activation and obesity can predict severe outcomes in COVID-19 patients.

The OEC and the RESC Alliance are working together to provide Quality Improvement Supports related to Standards, Curriculum, and Assessment for early childhood education providers.

Yale clinical fellow Attila Feher, MD, PhD, was selected for the American College of Cardiology (ACC) Young Author Achievement Award.

Since the appointment of Marcella Nunez-Smith, MD, MHS, as Director of the newly formed Center for Community Engagement and Health Equity (CEHE) within Smilow Cancer Hospital and Yale Cancer Center, the mission of ensuring cancer health equity and improving outcomes with an emphasis on traditionally marginalized communities, has begun to take shape.

Yale School of Medicine announces a gift to establish the Chênevert Family Brain Tumor Center at Yale Cancer Center. The Chênevert Family Brain Tumor Center will be a leading center in Neuro-Oncology research worldwide, bringing ground-breaking solutions and hope to patients with brain tumors.

Yale scientists have developed a new class of antiviral agents that shows promise for creating COVID-19 therapeutics — exhibiting particular effectiveness when used in tandem with the drug remdesivir, another antiviral medication approved for use against the virus.

For men with newly-diagnosed prostate cancer, numerous initial options are available. These include formal treatment options as well as a growing interest in active surveillance.

The hope is that PROTACs can treat other “undruggable” cancers that don’t respond to current treatments, including types of lung, breast, and colorectal cancers that may not have an active site on which a small-molecule drug or monoclonal antibody could bind.